BASFY Expands Liquid Enzyme Portfolio, Boosts Laundry Solutions

BASF SE BASFY has expanded its product portfolio of liquid enzymes to better serve the home care and I&I industry. With years of expertise, BASF has successfully integrated high-quality and high-performance enzymes into its product line, while ensuring sustainability and deep cleaning solutions. BASF has enhanced its range of liquid enzymes through the addition of lipase, cellulase and amylase offerings.

Building on its Lavergy product line, BASF has launched Lavergy L Pace, Lavergy C Care and Lavergy A Star. A liquid lipase product, Lavergy L Pace, has superior fat and oil stain removal ability at low temperatures. Lavergy C Care, a liquid care cellulase product, offers excellent fuzz and pill removal, best suited for cotton and cotton blend fabrics. The Lavergy A Star amylase biodegradable enzyme solution is effective in removing starch stains, offering a deeper clean.

BASF had already launched products like Lavergy M Ace, Lavergy C Bright and Lavergy Pro, building on its enzyme portfolio. With its in-depth technical know-how and innovation pipeline, BASF has positioned itself as one of the leaders in this industry.

BASFY stock has gained 9.7% over the past year compared with the industry’s 15.1% decline.

BASFY’s Zacks Rank & Key Picks

BASFY currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Royal Gold, Inc. RGLD,Coeur Mining, Inc.CDE andCarpenter Technology Corporation CRS. While RGLD and CDE currently sport a Zacks Rank #1 (Strong Buy) each, CRS carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for RGLD’s current-year earnings is pegged at $7.47 per share, indicating a 42% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 9%. RGLD’s shares have gained 18.7% in the past year.

The Zacks Consensus Estimate for CDE’s current-year earnings is pegged at 69 cents per share, implying a 283.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once, with an average surprise of 136.2%.

The Zacks Consensus Estimate for CRS’ fiscal 2025 earnings is pegged at $7.28 per share, indicating a rise of 53.6% from year-ago levels. The company’s earnings beat the consensus estimate in each of the trailing four quarters. Its shares have gained 150.6% in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research